Antibody conjugate formulations for selectively inhibiting VEGF
AssigneeBoard of Regents, The University of Texas System
InventorsPhilip E. Thorpe, Rolf A. Brekken
Life of this patent
Estimating the term…
Abstract
Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
Claims47
A composition comprising at least a first immunoconjugate comprising at least a first anti-VEGF antibody, or antigen-binding fragment thereof, that binds to substantially the same epitope as the monoclonal antibody 2C3 (ATCC PTA 1595) operatively attached to at least a first biological agent.
An immunoconjugate comprising at least a first anti-VEGF antibody, or antigen-binding fragment thereof, that binds to the same epitope as the monoclonal antibody 2C3 (ATCC PTA 1595) operatively attached to at least a first biological agent.
A composition comprising a biologically effective amount of at least a first immunoconjugate comprising at least a first biological agent operatively attached to an anti-VEGF antibody, or antigen-binding fragment thereof, that binds to the same epitope as the monoclonal antibody 2C3 (ATCC PTA 1595) and that significantly inhibits VEGF binding to the VEGF receptor VEGFR2 (KDR/Flk-1) without significantly inhibiting VEGF binding to the VEGF receptor VEGFR1 (Flt-1).
A pharmaceutical composition comprising a biologically effective amount of at least a first immunoconjugate comprising an anti-VEGF antibody, or antigen-binding fragment thereof, that binds to substantially the same epitope as the monoclonal antibody 2C3 (ATCC PTA 1595) operatively attached to at least a first biological agent.
Dependencies are inferred from the claim text.